This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This shift is benefiting pharmaceutical companies and contractresearchorganizations (CROs) by facilitating decentralized trials, simplifying patient recruitment and retention, and reducing the number of phase 3 clinical sites. Central contracts with retailers are providing convenient access to numerous trial locations.
This shift is benefiting pharmaceutical companies and contractresearchorganizations (CROs) by facilitating decentralized trials, simplifying patient recruitment and retention, and reducing the number of phase 3 clinical sites. Central contracts with retailers are providing convenient access to numerous trial locations.
This is fueling the growing demand for outsourcing, with contractresearchorganizations (CROs) and contract development and manufacturing organizations (CDMOs) driving industry growth. Conversely, small-to-mid, and emerging biopharma players, with 1 or 2 molecules in the pipeline, contribute over 16%.
San Antonio, TX — 7 th Aug, 2023 — Frost & Sullivan recently researched the Asia-Pacific biotechnology contractresearchorganization industry and, based on its findings, recognizes Avance Clinical with the 2023 Customer Value Leadership Award. In addition, the attractive 43.5%
Growing demand for outsourcing, with contractresearchorganizations (CROs) and contract development and manufacturing organizations (CDMOs) leading industry growth. Top 10 pharma companies contribute only 4-5% to R&D pipeline; top 25 contribute less than 10%.
Utilize this distinctive competitive benchmarking tool to elevate your future growth potential significantly. The Frost Radar™ serves as a powerful analytical tool for conducting a comprehensive ‘Growth Audit’ across various industries, evaluating key companies on essential criteria related to innovation and growth.
We organize all of the trending information in your field so you don't have to. Join 61,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content